5-Methoxy-diisopropyltryptamine

From The Lycaeum
Jump to: navigation, search
</th></tr></th></tr>
5-Methoxy-diisopropyltryptamine
215px
5-MeO-DiPT-3d-sticks.png
Systematic (IUPAC) name
3-[2-(Diisopropylamino)ethyl]-5-methoxyindole
Clinical data
Legal status Class A (UK) Schedule I (US)
Identifiers
CAS number 4021-34-5 7pxN
ATC code ?
PubChem CID 151182
DrugBank DB01441
ChemSpider 133247 7pxY
ChEBI CHEBI:48282 7pxY
Chemical data
Formula C17H26N2O 
Mol. mass 274.4
Physical data
Melt. point 181 °C (358 °F)
 14pxN (what is this?)  (verify)
5-MeO-DiPT tablets from Salem, Oregon

5-methoxy-diisopropyltryptamine (5-MeO-DiPT), often termed Foxy Methoxy or just Foxy, is a psychedelic tryptamine. 5-MeO-DiPT is orally active, and dosages between 6–20 mg are commonly reported. Many users note an unpleasant body load accompanies higher dosages. 5-MeO-DiPT is also taken by insufflation, or sometimes it is smoked or injected. Some users also report sound distortion, also noted with the related drug, DiPT.

Effects

Erowid reports the following effects:[1]

Positive

  • Mood lift, euphoria
  • Intensification of tactile sensations, smell, etc.
  • Sexually interesting
  • Emotionally opening
  • Diminished aggression, hostility, and jealousy
  • Diminished fear, anxiety, and insecurity
  • Improved self-confidence
  • Substantial enhancement of the appreciation for quality of music
  • Increased energy and endurance

Neutral

  • Out-of-body experience, dissociation
  • Feelings of body & muscle energy, buzzing
  • Auditory distortions, pitch shifts
  • Visual distortions, open and closed-eye patterning, movement trails, shifting colors
  • Physical and mental stimulation

Negative

  • Possible stomach discomfort, gas & vomiting
  • Possible minor jaw-clenching
  • Possible Diarrhea
  • Anxious stimulation
  • Muscle tension / discomfort
  • Possible male impotence for duration of drug's effects during higher doses
  • Panic Attacks

Pharmacology

The mechanism that produces the hallucinogenic and entheogenic effects of 5-MeO-DiPT is thought to result primarily from 5-HT2A receptor agonism, although additional mechanisms of action such as MAOI may be involved also.[2]

Overdosage

Excessive doses have caused clinical intoxication, characterized by nausea, vomiting, agitation, hypotension, mydriasis, tachycardia and hallucinations, in a number of young adults. Rhabdomyolysis and renal failure occurred in one young man and another one died 3–4 hours after an apparent rectal overdose.[3] A 24 year old man also died of this compound being administered into the colon. http://bitnest.ca/external.php?id=%257DbxUgY%255CC%2540%251BR%252B8%253CW%255C%250E%2505%2515%251CVIwx%257E%2514TwxEA

Drug prohibition laws

Denmark

Illegal since February 2004.

Germany

Illegal since September 1999.

Greece

Illegal since February 2003.

Japan

Illegal since April 2005.

Singapore

Illegal since early 2006.

Sweden

Sveriges riksdags health ministry Statens folkhälsoinstitut classified 5-MeO-DiPT as "health hazard" under the act Lagen om förbud mot vissa hälsofarliga varor (translated Act on the Prohibition of Certain Goods Dangerous to Health) as of Oct 1, 2004, in their regulation SFS 2004:696 listed as 5-metoxi-N,N-diisopropyltryptamin (5-MeO-DIPT), making it illegal to sell or possess.[4]

USA

On April 4, 2003, the United States DEA added both 5-MeO-DiPT and AMT to Schedule I of the Controlled Substances Act under "emergency scheduling" procedures. The drugs were officially placed into Schedule I on September 29, 2004. Prior to its prohibition in the U.S., 5-MeO-DiPT was sold online alongside psychoactive analogues like DiPT, and DPT neither of which have yet been expressly outlawed in that country. However, in July 2004, Operation Web Tryp was concluded, confirming that U.S. Federal law enforcement intends to prosecute sale of these analogs of 5-MeO-DiPT. Previous prosecutions under the Federal Analog Act have met, on occasion, with failure, given some court rulings regarding possible unconstitutional vagueness regarding what substances are properly considered 'analogs'; such issues may be addressed on appeal.

See also

References

  1. Erowid 5-MeO-DIPT Vault : Effects
  2. Nagai F, Nonaka R, Satoh Hisashi Kamimura K (March 2007). "The effects of non-medically used psychoactive drugs on monoamine neurotransmission in rat brain". European Journal of Pharmacology 559 (2-3): 132–7. PMID 17223101. doi:10.1016/j.ejphar.2006.11.075. 
  3. R. Baselt, Disposition of Toxic Drugs and Chemicals in Man, 8th edition, Biomedical Publications, Foster City, CA, 2008, pp. 975-976.
  4. http://www.notisum.se/rnp/sls/sfs/20040696.pdf

External links

      
Personal tools
Namespaces

Variants
Actions
Navigation
Forums
Lycaeum IRC Chat
TheAntiDrug Diaspora
Starting Points
Tools
Print/export